Prior Authorization and Documentation Expected

Prior authorization may be required for nasal surgical procedures; medical records documentation should be provided to support medical necessity. All nasal surgical claims may be subject to coding review to determine reconstructive vs cosmetic intent.

• PA implied for listed nasal surgical codes (see Applicable Codes) — submit clinical documentation with request
• Medical records must be legible and available upon request

Prior Authorization — Not Always Explicit

Prior authorization is not explicitly specified for every procedure in the excerpt; however, requests for procedures addressing nasal airway obstruction (NAO) due to valve collapse should include documentation of the cause and baseline symptom severity to allow coverage determination.

• If PA is not specifically required by plan documents, documentation may still be requested during claim review
• Submit photos, exam findings, and validated baseline scores (e.g., NOSE, rTNSS) with any request

Prior Authorization: Document NAO Due to Valve Collapse and Baseline NOSE

When seeking authorization for procedures to treat NAO due to nasal valve collapse, document that NAO is due primarily to valve collapse and include a baseline NOSE score and objective/photographic evidence of dynamic or static valve compromise.

• Document visible collapse of alar cartilage and/or lateral nasal wall with deep inspiration
• Include modified Cottle maneuver findings and photos demonstrating dynamic collapse
• Include baseline NOSE Scale (and follow-up plans) in the medical record

Procedures Using Absorbable Nasal Cartilage Support Implants

Procedures using absorbable nasal cartilage support implants (e.g., Latera) should be documented with indication that dynamic nasal valve collapse is a main contributor to NAO and that patients have undergone appropriate stepwise management prior to implant placement.

• Describe device used (Latera is the FDA-approved absorbable implant) and that insertion is via minimally invasive intranasal approach
• Provide rationale for implant versus alternative surgical options and note any concurrent procedures

Evidence Quality and Follow-up Limitations

Available evidence for absorbable nasal implants and some valve/radiofrequency procedures is promising but overall of low quality with inadequate long-term follow-up and limitations in study design.

• Many studies have short follow-up (often 3–12 months) or lack robust control arms
• Single-center, small-sample, or nonrandomized designs are common

Evidence Limitations May Trigger Additional Documentation or Denials

Limitations in the evidence base (short follow-up, lack of controls, risk of bias) may lead UnitedHealthcare to request additional documentation or to deny coverage when medical necessity cannot be adequately demonstrated.

• Lack of objective measures or comparator groups can increase denial risk
• Significant loss to follow-up in studies reduces certainty about durability

Evidence Insufficiency Risk

Evidence insufficiency (high risk of bias, short-term outcomes only, or inconclusive clinical impact) creates a higher risk that requests for novel or less-established interventions will be restricted or denied unless robust supporting documentation is provided.

• Provide long-term outcome data where available and clearly document objective measures and symptom scores
• If evidence is limited, include rationale for why alternative treatments are unsuitable or have failed

Treatment Sequencing Considerations

Treatment sequencing should be evident in the record: evaluate and treat other causes of nasal obstruction and attempt appropriate conservative therapies before invasive procedures. When multiple anatomic contributors exist, sequence or combine treatments as clinically indicated.

• Ensure other causes (rhinosinusitis, polyposis, turbinate hypertrophy, septal deviation) have been addressed or are planned for concurrent correction
• Document rationale for proceeding with valve-focused procedure when coexisting pathology exists

Society Guidance Supports Use of FDA‑Approved Biomaterials

Society guidance (AAO-HNS, ARS) supports the use of FDA‑approved biomaterials such as bioabsorbable implants in selected patients and recommends clinician judgment guided by evidence, experience, and patient preference.

• AAO-HNS recognizes surgical repair options including implants and emphasizes treating other causes of NAO to optimize outcomes
• AAO-HNS (2025) supports use of FDA-approved biomaterials in sinonasal procedures when clinically appropriate
• ARS (2022) supports bioabsorbable implants as an effective option for NAO due to valve collapse in selected patients

Stepwise Therapy Expectation

Stepwise therapy is expected: document adequate conservative medical management and failure of appropriate medical therapies (eg, intranasal steroids, antihistamines, anticholinergics) prior to device-based or surgical interventions when clinically indicated.

• Conservative management duration often described as ≥4 weeks (or longer per specific indication); for chronic rhinitis trials often >6 months with defined rTNSS thresholds
• For PNN procedures, document failed medical management including topical agents and duration

Medical Records and Documentation Requirements

Medical records documentation may be requested during review and must fully support the medical necessity of the requested service. Documentation should include history, physical exam, diagnostic testing, validated symptom scores, photographs, and a clear surgical plan indicating why the proposed intervention is needed.

• Records must be legible and available upon request
• Include baseline and follow-up NOSE and/or VAS scores when applicable, modified Cottle maneuver findings, and photographic evidence of valve collapse